sST2 levels are associated with all‐cause mortality in anticoagulated patients with atrial fibrillation

Vı́lchez, Juan Antonio; Pérez-Cuellar, Montserrat; Marín, Francisco; Gallego, Pilar; Manzano‐Fernández, Sergio; Valdés, Mariano; Vicente, Vicente; Noguera-Velasco, José Antonio; Lip, Gregory Y.H.; Ordóñez-Llanos, Jordi; Roldán, Vanessa

doi:10.1111/eci.12482

Cited by 22 publications

(18 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our group [35] validated for the first time, the predictive value of sST2 in atrial fibrillation (AF) patients and concluded that sST2 levels had independent predictive value for all-cause mortality. Indeed, several groups have demonstrated the role of sST2 in cardiovascular events [36,37].…”

Section: Detection Of Central Venous Catheter-related Bloodstream Infmentioning

confidence: 96%

“…sST2 levels are associated with all-cause mortality in anticoagulated patients with atrial fibrillation [35] (Mar ıa Asunci on Esteve-Pastor and Francisco Mar ın)…”

Section: Detection Of Central Venous Catheter-related Bloodstream Infmentioning

confidence: 99%

“…These findings strongly suggest an abnormal remodeling process in cardiac tissue in AATD. X [35] In an anticoagulated atrial fibrillation (AF) patient's cohort, soluble suppression of tumorigenicity 2 (sST2) levels are an independent predictive factor of all-cause mortality. sST2 levels could be a biomarker used to improve clinical risk assessment in anticoagulated AF patients.…”

Section: A1-mentioning

confidence: 99%

“…sST2 levels are associated with all-cause mortality in anticoagulated patients with atrial fibrillation [35] (Mar ıa Asunci on Esteve-Pastor and Francisco Mar ın) Soluble suppression of tumorigenicity 2 (sST2) is the soluble form of the receptor protein for interleukin-1 family, and its expression is induced in response to myocardial stress. Our group [35] validated for the first time, the predictive value of sST2 in atrial fibrillation (AF) patients and concluded that sST2 levels had independent predictive value for all-cause mortality. Indeed, several groups have demonstrated the role of sST2 in cardiovascular events [36,37].…”

Section: Detection Of Central Venous Catheter-related Bloodstream Infmentioning

confidence: 99%

See 3 more Smart Citations

Research update for articles published in EJCI in 2015

et al. 2017

Self Cite

View full text Add to dashboard Cite

Section: Detection Of Central Venous Catheter-related Bloodstream Infmentioning

confidence: 96%

“…sST2 levels are associated with all-cause mortality in anticoagulated patients with atrial fibrillation [35] (Mar ıa Asunci on Esteve-Pastor and Francisco Mar ın)…”

Section: Detection Of Central Venous Catheter-related Bloodstream Infmentioning

confidence: 99%

Section: A1-mentioning

confidence: 99%

Section: Detection Of Central Venous Catheter-related Bloodstream Infmentioning

confidence: 99%

See 2 more Smart Citations

Research update for articles published in EJCI in 2015

et al. 2017

Self Cite

View full text Add to dashboard Cite

“…Thus, sST2 may play part in the inflammatory process of diabetes mellitus, although the mechanisms behind this are not yet fully understood. Levels of sST2 have been associated with cardiovascular complications and mortality [20, 21] and suggested to have a prognostic value as risk predictor in patients with ambulatory chronic heart failure [22]. …”

Section: Introductionmentioning

confidence: 99%

Soluble plasma proteins ST2 and CD163 as early biomarkers of nephropathy in Swedish patients with diabetes, 15–34 years of age: a prospective cohort study

Samuelsson

Dereke

Svensson

et al. 2017

Diabetol Metab Syndr

View full text Add to dashboard Cite

BackgroundThe aim of this study was to investigate plasma levels of sST2 and sCD163 to determine whether they at an early stage could predict development of diabetic nephropathy and/or diabetic retinopathy in patients at clinical onset.MethodsPatients diagnosed with diabetes mellitus at age 15–34 years between 1987 and 1988 (n = 220) were included. Data such as BMI, smoking, HbA1c and islet cell antibodies were collected at time of diagnosis. Within the 10 year follow-up period, 112 patients (51%) developed following diabetes related complications; retinopathy (n = 91), nephropathy (n = 12) or both (n = 9). Plasma concentrations of sST2 and sCD163 were measured at time of diagnosis and levels compared between different complication groups.ResultsPlasma levels of sST2 were significantly higher in patients who later developed nephropathy (n = 21; 1012 [773–1493] pg/ml) compared to those who did not (n = 199; 723 [449–1084] pg/ml; p = 0.006). A tendency for higher plasma levels of sCD163 was observed but not statistically significant (p = 0.058).ConclusionssST2 and sCD163 show promise as potential biomarkers for the development of nephropathy already at clinical onset. sST2 and/or sCD163 could possibly be part of a biomarker panel aimed to find patients at high risk of developing nephropathy. Both markers need to be investigated in a larger prospective study.

show abstract

Soluble ST2 in the prediction of heart failure and death in patients with atrial fibrillation

Krittayaphong

Pumprueg

Sairat

2022

Clinical Cardiology

View full text Add to dashboard Cite

Background: Biomarkers may be a useful marker for predicting heart failure (HF) or death in patients with atrial fibrillation (AF).Hypothesis: Soluble ST2 (sST2) may be a good biomarker for the prediction of HF or death in patients with AF.Methods: This is a prospective study of patients with nonvalvular AF. Clinical outcomes were HF or death. Clinical and laboratory data were compared between those with and without clinical outcomes. Univariate and multivariate analysis was performed to determine whether sST2 is an independent predictor for heart failure or death in patients with nonvalvular AF.Results: A total of 185 patients (mean age: 68.9 ± 11.0 years) were included, 116 (62.7%) were male. The average sST2 and N-terminal pro-brain natriuretic peptide (NT-proBNP) levels were 31.3 ± 19.7 ng/ml and 2399.5 ± 6853.0 pg/ml, respectively. Best receiver operating characteristic (ROC) cut off of sST2 for predicting HF or death was 30.14 ng/ml. Seventy-three (39.5%) patients had an sST2 level ≥30.14 ng/ml, and 112 (60.5%) had an sST2 level <30.14 ng/dl. The average follow-up was 33.1 ± 6.6 months. Twenty-nine (15.7%) patients died, and 33 (17.8%) developed HF during follow-up. Multivariate analysis revealed that high sST2 to be an independent risk factor for death or HF with a HR and 95% CI of 2.60 (1.41-4.78). The predictive value of sST2 is better than NT-proBNP, and it remained significant in AF patients irrespective of history of HF, and NT-proBNP levels.

show abstract

sST2 levels are associated with all‐cause mortality in anticoagulated patients with atrial fibrillation

Abstract: In an anticoagulated AF patient's cohort, sST2 levels are an independent predictive factor of all-cause mortality. sST2 levels could be a biomarker used to improve clinical risk assessment in anticoagulated AF patients.

Cited by 22 publications

References 31 publications

Research update for articles published in EJCI in 2015

Research update for articles published in EJCI in 2015

Soluble plasma proteins ST2 and CD163 as early biomarkers of nephropathy in Swedish patients with diabetes, 15–34 years of age: a prospective cohort study

Soluble ST2 in the prediction of heart failure and death in patients with atrial fibrillation

Contact Info

Product

Resources

About